Major Depressive Disorder Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies,

Major Depressive Disorder Pipeline constitutes 75+ key companies continuously working towards developing 75+ Major Depressive Disorder treatment therapies, analyzes DelveInsight.

Major Depressive Disorder Overview:

Major Depressive Disorder (MDD), also known as clinical depression, is a serious mental health condition that can affect various aspects of your life. It influences mood, behavior, and physical functions like appetite and sleep. The exact cause of MDD is unclear, but several factors can raise the risk of developing it. To be diagnosed, symptoms must persist for at least two weeks, with at least one symptom being a depressed mood or a loss of interest or pleasure. Treatment for MDD typically includes medication and psychotherapy, and certain lifestyle changes may also help alleviate some symptoms.

Request for a detailed insights report on Major Depressive Disorder pipeline insights @ https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Major Depressive Disorder Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Major Depressive Disorder Therapeutics Market.

Key Takeaways from the Major Depressive Disorder Pipeline Report

DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
In December 2023, Cybin IRL Limited announced a Phase 1 and 2 clinical trial study for CYB003. The study aims to assess the safety and tolerability of increasing oral doses of CYB003 in both healthy participants and those with major depressive disorder (MDD).
In November 2023, Neumora Therapeutics Inc. launched a Phase 3 clinical trial for NMRA 335140. This randomized, double-blind, placebo-controlled, multicenter study is designed to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on depressive symptoms in individuals with MDD. The study includes a Screening Period of up to 28 days, followed by a 6-week Treatment Period where participants receive either NMRA 335140 or a placebo. Participants who complete the study, provide informed consent, and meet eligibility criteria may have the opportunity to enroll in an extension study (NMRA 335140 501).
In October 2023, Neumora Therapeutics Inc. also announced another Phase 3 clinical trial for NMRA 335140, structured similarly as a randomized, double-blind, placebo-controlled, multicenter study. It aims to assess the impact of NMRA 335140 on depressive symptoms in individuals with MDD. The study design includes a Screening Period of up to 28 days and a 6-week Treatment Period, after which eligible participants may continue in an extension study (NMRA 335140 501).
Additionally, in October 2023, Intra-Cellular Therapies Inc. initiated a Phase 3 clinical trial for Lumateperone. This multicenter, randomized, double-blind, placebo-controlled study focuses on patients diagnosed with MDD, according to DSM-5 criteria, who have shown an inadequate response to ongoing antidepressant therapy (ADT).
Key Major Depressive Disorder companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others are evaluating new drugs for Major Depressive Disorder to improve the treatment landscape.
Promising Major Depressive Disorder pipeline therapies in various stages of development include SAGE-217, REL-1017, Seltorexant, SP-624, SPL026, PDC-1421, and others.

Major Depressive Disorder Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Major Depressive Disorder Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Major Depressive Disorder market.

Download our free sample page report on Major Depressive Disorder pipeline insights @ https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder Emerging Drugs

SAGE-217: Sage Therapeutics
REL-1017: Relmada Therapeutics, Inc
Seltorexant: Minerva Sciences
SP-624: Sirtsei Pharmaceuticals, Inc.
SPL026: Small Pharma
PDC-1421: BioLite Inc

Major Depressive Disorder Companies

Over 75 key companies are working on developing therapies for Major Depressive Disorder. Among them, SAGE Therapeutics has drug candidates for the condition in the most advanced stage, Preregistration.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Major Depressive Disorder Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Major Depressive Disorder Therapies and Key Companies: Major Depressive Disorder Clinical Trials and advancements @ https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder Pipeline Therapeutic Assessment
• Major Depressive Disorder Assessment by Product Type
• Major Depressive Disorder By Stage
• Major Depressive Disorder Assessment by Route of Administration
• Major Depressive Disorder Assessment by Molecule Type

Download Major Depressive Disorder Sample report to know in detail about the Major Depressive Disorder treatment market @ Major Depressive Disorder Therapeutic Assessment @ https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Major Depressive Disorder Current Treatment Patterns
4. Major Depressive Disorder - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Major Depressive Disorder Late-Stage Products (Phase-III)
7. Major Depressive Disorder Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Major Depressive Disorder Discontinued Products
13. Major Depressive Disorder Product Profiles
14. Major Depressive Disorder Key Companies
15. Major Depressive Disorder Key Products
16. Dormant and Discontinued Products
17. Major Depressive Disorder Unmet Needs
18. Major Depressive Disorder Future Perspectives
19. Major Depressive Disorder Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Major Depressive Disorder Pipeline Reports Offerings: https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.